Investor Relations
Invest in the Future of Human Health
Transforma Bio is seeking strategic partners and investors who share our conviction that the next generation of human health breakthroughs will come from the intersection of precision gene therapy, medical devices, and nature-derived anti-ageing science.
Investment Thesis
Three High-Growth Verticals. One Unified Platform.
We have structured Transforma Bio to capture value across three distinct but complementary life sciences markets — rare disease gene therapy, medical devices, and the rapidly expanding longevity and anti-ageing sector. Our sturgeon ECM platform alone addresses a global nutraceutical and cosmeceutical market projected to exceed $100 billion by 2030.
Rare Disease
Gene & Cell Therapy
High-value orphan drug designations, accelerated regulatory pathways, and premium pricing in an underserved patient population.
MedTech
Medical Devices
Complementary device innovations that enhance therapeutic delivery and patient monitoring across our pipeline programmes.
Longevity & Wellness
Food, Health & ECM Anti-Ageing
Sturgeon ECM nutraceuticals and cosmeceuticals targeting the global longevity market — oral and topical formulations with strong IP potential.
Get in Touch
Start a Conversation
Whether you are a venture investor, family office, strategic partner, or patient advocacy group — we welcome your enquiry. Complete the form below and a member of our team will respond within two business days.
This page contains forward-looking statements and projections. Nothing on this page constitutes an offer of securities, investment advice, or a solicitation to invest. All investment involves risk. Market size projections are based on third-party industry reports and are not guaranteed.